Skip to main content
. 2019 Jun 21;11:5557–5572. doi: 10.2147/CMAR.S203060

Figure 3.

Figure 3

IRF6 enhances dose-dependent sensitivity to cisplatin (CDDP) and suppresses the breast tumorigenicity. (A) The cells were seeded with different doses of cisplatin. Representative photos and the survival index of the formed colonies are presented. Student’s t-test, *p<0.05. (B) The cells treated with increasing doses of cisplatin followed by Western blotting analysis of caspase-3 and cleaved caspase-3 expression. (C) Images (left panel) and quantification of the number of oncospheres (right panel) formed in transiently transfected cell lines in DMEM/F12 medium with a 20 ng/mL concentration of FGF and EGF for 6–7 days. Student’s t-test, **p<0.01.  (D) Tumorigenesis abilities: stabled IRF6-overexpressing cells in five cell concentrations were injected subcutaneously into the right and left armpits of nude mice and observed for 20 days. The tumor formation rates in different groups are shown and the right upper panel shows photographs of their respective isolated tumors.